WO2008026507A1 - Agent de blanchiment de la peau - Google Patents

Agent de blanchiment de la peau Download PDF

Info

Publication number
WO2008026507A1
WO2008026507A1 PCT/JP2007/066382 JP2007066382W WO2008026507A1 WO 2008026507 A1 WO2008026507 A1 WO 2008026507A1 JP 2007066382 W JP2007066382 W JP 2007066382W WO 2008026507 A1 WO2008026507 A1 WO 2008026507A1
Authority
WO
WIPO (PCT)
Prior art keywords
hop
cold water
whitening agent
water extract
dried
Prior art date
Application number
PCT/JP2007/066382
Other languages
English (en)
Japanese (ja)
Inventor
Yuki Narita
Syuichi Segawa
Yasukazu Nakakita
Yoshihiro Takata
Original Assignee
Sapporo Breweries Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sapporo Breweries Limited filed Critical Sapporo Breweries Limited
Priority to JP2008532036A priority Critical patent/JPWO2008026507A1/ja
Publication of WO2008026507A1 publication Critical patent/WO2008026507A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/602—Glycosides, e.g. rutin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin

Definitions

  • the present invention relates to a whitening agent.
  • Hops are an indispensable raw material for beer production, and are said to give bitterness and aroma to beer, improve foaming and foam retention, improve clarity, and suppress the propagation of germs. Hops have pharmacological effects such as healthy stomach and digestion promotion, and have been used as medicinal plants.
  • Patent Document 1 a heat-resistant acidophilic bacterial growth inhibitor containing hop extract as an active ingredient
  • Patent Document 2 a flavor improver for processed rice foods containing hop extract as an active ingredient
  • Patent Document 4 a hop extract Applications such as a bathing agent (Patent Document 3) and a hop extract having an active oxygen scavenging action (Patent Document 4) have been proposed!
  • a hop extract as a topical skin preparation is also being considered.
  • a topical skin preparation containing a component extracted from a plant body of the genus Candidace An example of the extract is a hop extract (Patent Document 5).
  • Patent Document 1 JP 2005-137241
  • Patent Document 2 JP 2005 269988
  • Patent Document 3 JP-A-9 67245
  • Patent Document 4 JP-A-4 202138
  • Patent Document 5 Japanese Patent Laid-Open No. 2003-300859
  • hops contain many extractable components
  • extracts with different compositions can be obtained if extraction conditions such as extraction medium and extraction temperature are different.
  • the effect of the extract is also different. Therefore, even when the hop extract is applied as a component of a skin external preparation, the effect of the external preparation such as a whitening effect is often insufficient depending on the extraction conditions.
  • an object of the present invention is to provide a whitening agent that contains a hop extract and is particularly excellent in whitening effect.
  • the present invention provides a whitening agent comprising a cold water extract of hop tissue as an active ingredient.
  • the hop extract by cold water extraction is: astragalin, astragalin malonyl darcoside, isoquercitrin, isoquercitrin malonyl darcoside, quercetin malonyl da norcoside, kaempferol rutinoside, kenferrol malonyl darcoside
  • Fluoroacyfuphenone derivatives that contain at least one flavonoid glycoside selected from the group consisting of rutin and fluorosilenone glycosides are preferred as fluoroisobutyrophenone 2-O— ⁇ -D-Gnolecopyranoside, 1-Methylolebutyrophenone 2- 2 -—- ⁇ -D-Gnolecopyranoside and Fluoroisovalerophenone 2-0.1 ⁇ -D-Gnolecopyranoside At least one selected from the group consisting of
  • the hop tissue is preferably a hop stem, bulbous flower, or leaf. S is preferable, and a dried hop koji pulverized product is particularly preferable. From the same point of view, it is preferable that the hop tissue is obtained by removing at least a part of the pulverized product of lupurin or less from the pulverized product of dried hops, and pulverizing the dried hops. As the product, a pulverized product of dried hop bulbs can be used. As the hop organization, a hop residue obtained by removing at least a part of a substance extracted from a dried hop bulb by organic solvent extraction or supercritical fluid extraction from the hop bulb is also used. Good.
  • Such a whitening agent can be used as an external preparation for skin or one component thereof, but also functions as an ingestible whitening agent.
  • a whitening agent containing a hop extract and particularly excellent in whitening effect is provided.
  • FIG. 2 HPLC chart of flavonol fraction extracted from hop (Czech zazat) pellets with water.
  • FIG. 3 is a graph showing the tyrosinase activity inhibition rate (%) of cold water extract A and cold water extract B.
  • FIG. 4 is a graph showing the tyrosinase activity inhibition rate (%) of cold water extract C as a relative value when the control tyrosinase activity inhibition rate is 0%.
  • FIG. 5 is a graph showing the cell viability (%) of melanoma cells when cold water extract A is added in Example 2 as a relative value when the cell viability of a control is 100%.
  • FIG. 6 is a photographic diagram showing the whitening state of melanoma cells and the result of visual determination when cold water extract A is added in Example 2.
  • FIG. 7 is a graph showing the cell viability (%) of melanoma cells when cold water extract B is added in Example 2 as a relative value when the cell viability of a control is 100%.
  • FIG. 8 is a photographic diagram showing the whitening status of melanoma cells and the results of visual judgment when cold water extract B is added in Example 2.
  • FIG. 9 is a graph showing the cell viability (%) of melanoma cells when cold water extract C is added in Example 2 as a relative value when the cell viability of a control is 100%.
  • FIG. 10 is a photographic diagram showing the whitening state of melanoma cells and the result of visual judgment when cold water extract C is added in Example 2.
  • FIG. 11 (a) is a perspective view showing the structure of the skin model cup, and (b) is a cross-sectional view showing the structure of the skin model cup.
  • FIG. 12 is a graph showing the tissue cell viability when cold water extract A is added in Example 3 as a relative value when the control viability is 100%.
  • FIG. 13 is a photograph showing the melanin production status of the control in Example 3.
  • FIG. 14 is a photograph showing the state of melanin production in Example 3 when a 0.08% by mass solution of cold water extract A was added.
  • FIG. 15 is a photograph showing the melanin production state in Example 3 when a 0.008 mass% solution of cold water extract A was added.
  • the active ingredient of the whitening agent of the present invention is a cold water extract of hop tissue, and hops of any varieties can be targeted for cold water extraction.
  • the whitening effect of the extracted components is high, so we prefer Czech brewing varieties, such as Czech Zach, German Haratau tradition, domestic Furano No. 18 and Chinese.
  • Czech zhaza is particularly preferred.
  • the hop organization means a hop! /, Any organization or a part thereof.
  • the hop tissue used for cold water extraction is more preferably a hop koji that prefers a bulbous flower that is any of leaves, stems, and bulbous flowers.
  • the hop bud is a cocoon leaf constituting the bulb flower, and can be obtained by removing at least a part of the bulb flower force and the lupulin portion (yellow granule).
  • the hop tissue used for cold water extraction of the present invention may be a hop koji that is discarded without being pulverized to a specified size when processing hop pellets used for brewing foaming alcoholic beverages such as beer. It may be a hop residue remaining after extracting the hop bulbs described later with a supercritical fluid or an organic solvent.
  • the cold water extract of hop tissue is obtained by a production method comprising a step of extracting hop tissue with cold water.
  • cold water means water at room temperature or lower, and usually refers to water at temperatures above 0 ° C and below 50 ° C.
  • the temperature of chilled water is preferably more than 0 ° C and 40 ° C or less, more preferably 5 ° C or more and 30 ° C or less, and more preferably 10 ° C or more and 30 ° C or less 20 ⁇ 5 ° C (Moreover, 20 ⁇ 3 ° C) is particularly preferable.
  • a method for obtaining an extract from a hop tissue a method of water extraction of a natural product from a plant can be widely adopted.
  • a hop tissue and a certain amount of cold water are placed in a container and appropriately stirred for a predetermined time.
  • the method of leaving still and filtering an extract liquid and removing a residue is mentioned.
  • the filtered extract can be further centrifuged, and its supernatant (hereinafter referred to as centrifugal supernatant) can be used as a cold water extract.
  • the obtained cold water extract can be concentrated and dried for use.
  • the cold water extract of hop tissue can be used after being purified through a column packed with a synthetic adsorbent.
  • the synthetic adsorbent include Amberlite XAD-4, 7, and 16 (Onoregano), activated carbon, and polybulupolypyrrolidone (PVPP; polyphenol adsorbent).
  • Amberlite XAD-4 is preferably used.
  • a cold water extract of hop tissue is passed through a column packed with a synthetic adsorbent, and the adsorbed component is eluted with, for example, a mixed solvent of water and methanol, and the eluted fraction can be used.
  • the whitening agent of the present invention preferably has a cold water extract of a dried hop kneaded pulverized product as an active ingredient. It is preferable to use a cold water extract from which at least a part of the pulverized product has been removed as an active ingredient.
  • the pulverized dried hop bulbs used for cold water extraction are, for example, a drying step for drying hop bulbs to obtain dried hop bulbs, a pulverizing step for pulverizing dried hop bulbs to obtain a pulverized product, and the like. And a sorting step for removing the pulverized material having a size smaller than that of Lubrin from the pulverized material.
  • the hop bulbs are dried at a temperature of 100 ° C or less and the water content can be removed to such an extent that the hop bulbs can be stored. It is preferred to dry to ⁇ 9%.
  • the hop bulbs can be efficiently pulverized into fine powders.
  • a pulverizer such as a pin mill, a hammer mill, or a ball mill may be used.
  • the pulverized product is sieved, for example, the pulverized product whose major axis is 0.1 mm or more. Can be selected as “larger than Lubrin”.
  • the major axis not to pass through the sieve it is preferable to set the major axis not to pass through the sieve to a major axis of 0.3 mm or more, and the major axis of 0.5 mm or more is preferable to the force S! /.
  • the dried hops pulverized products are sieved with a 0.1, 0.3 or 0.5 mm sieve. What is necessary is just to collect the pulverized material which did not pass through.
  • the cold water extract obtained by removing at least a part of the pulverized product having a size smaller than the size of Lubrin from the pulverized product of the dried hop bulb flower is obtained by adding the pulverized dried hop bulb flower thus selected to the cold water described above. Extraction may be performed by the method described in the extracting step.
  • the pulverized product of dried hop bulbs used in the present invention is a pulverized product of frozen hop bulbs! /.
  • the method for freezing the dried hops is not particularly limited, but the freezing temperature is preferably 10 ° C or lower, more preferably -35 ° C or lower.
  • the cold water extract is a hop residue obtained by removing at least a part of a substance extracted from a dried hop bulb by organic solvent extraction or supercritical fluid extraction from the hop bulb. It can be a cold water extract.
  • the organic solvent used for the organic solvent extraction include alcohol or hexane, and ethanol is more preferable, which is a lower alcohol having 1 to 4 carbon atoms.
  • the supercritical fluid used for supercritical fluid extraction include carbon dioxide, water, methane, ethane, ethylene, propane, pentane, methanol, and ethanol, and carbon dioxide is preferred.
  • the cold water extract is typically astragalin, astragalin malonyl darcoside, isokenorecitrin, isoquercitrin malonyl darcoside, quercetin malonyl darcoside, kenferrono lenretinoside, kenferrono remarono gnono Contains at least one flavonoid glycoside selected from the group consisting of recoside, noretin and fluoroacinole phenone glycoside
  • fluorosilphenone glycoside can be represented by the following general formula (1).
  • R 1 represents an isopropyl group, an isobutyl group or a sec-butyl group.
  • a fluorosilphenone glycoside is represented by the following formula (2): fluoroisobutyrophenone 2-O- ⁇ -D-gnoleco
  • the fluorosilphenone glycoside is represented by the following formula (3): Floro 2-methinolevyllophenone-2-0.1 ⁇ -D—
  • the fluorosilvalenone glycoside is represented by the following formula (4): fluoroisovalerophenone 2-O- ⁇ -D —Gnorecopyranoside.
  • the content of the cold water extract of the hop tissue in the whitening agent is preferably from 0.0001 to 100% by mass based on the total amount of the whitening agent as a component excluding the extraction medium; 100% by mass is more preferable;! To 100% by mass is more preferable 5 to 100% by mass is particularly preferable.
  • the whitening agent is a hop tissue cold water extract as well as a wetting agent, an oil component, a moisturizing agent, a powder, a dye, an emulsifier, a dispersion aid, a solubilizer, a cleaning agent, an ultraviolet absorber, a thickening agent. It may contain agents, drugs, fragrances, resins, excipients, antibacterial and antifungal agents, deodorants and deodorants, enzymes, purified water, and alcohol. Moreover, you may add another whitening agent.
  • the whitening agent of the present invention is applied to the skin as a skin external preparation having a whitening effect by itself. It can also be used as a whitening effect-imparting agent that is added to cosmetics and drugs to impart a whitening effect thereto. Furthermore, it can be used as an oral ingestion-type whitening agent that exhibits a whitening effect when taken.
  • Hops (Domestic Furano No. 18) leaves were chopped, soaked in 10 times (w / v) distilled water, and allowed to stand at 5 ° C. This was centrifuged at 9200G for 15 minutes, and the supernatant was collected to obtain a cold water extract of hop leaves.
  • the obtained cold water extract was transferred to a separatory funnel, hexane was added, and the hexane transfer component was discarded. Further, ethyl acetate was added to the aqueous layer, and the ethyl acetate transfer component was discarded. Finally, n-butanol was added to the aqueous layer, and the butanol layer obtained by repeating the butanol extraction operation three times was combined, and concentrated under reduced pressure to obtain a flavonol fraction (flavonoid glycoside separated from the cold water extract of hop tissue).
  • each peak of the flavonol fraction was separated by preparative HPLC, and the components of each peak were identified.
  • a C18 column (Waters SunFire) was used at 40 ° C, and the flow rate was 6 mL / min.
  • the mobile phase was a linear gradient in which 10% MeCN was maintained for 10 minutes and then changed to 60% MeCN over 150 minutes. Detection was performed with a 350 nm UV detector.
  • Figure 1 shows the HPLC analysis results.
  • the flavonol fraction of the cold water extract of hop leaves has three main peaks. Existed and these were all identified as kaempferol glycosides. Specifically, the peak indicated by 1 in FIG. 1 was kaempferol rutinoside, the peak indicated by 2 was astragalin, and the peak indicated by 3 was kaempferol malonyl darcoside.
  • Hops (Czech zazat) type 90 pellets lkg was placed in 10 L of distilled water, and the pellets were removed while stirring properly at 20 ° C. This was centrifuged at 9200G for 15 minutes. As a centrifuge, Hitachi CR21G was used. After centrifugation, the supernatant was collected and further concentrated to obtain 150 g of a concentrated liquid (hereinafter referred to as cold water extract A).
  • cold water extract A a concentrated liquid
  • FIG. 2 shows the results of HPLC analysis.
  • the flavonol fraction of cold water extract A which are kaempferol glycosides (astragalin and kaempferol malonyl darcoside) and quercetin malonyl dalcoside.
  • the peak indicated by 1 in FIG. 2 was kaempferol malonyl darcoside
  • the peak indicated by 2 was astragalin
  • the peak indicated by 3 was quercetin malonyl darcoside.
  • the peak indicated by 4 was rutin
  • the peak indicated by 5 was isoquercitrin
  • the peak indicated by 6 was kaempferol rutinoside.
  • cold water extract B concentrated liquid
  • L-tyrosine 40 mg and MilliQ water were added to the container to make lOOmL.
  • the container was warmed in a beaker containing hot water.
  • L-tyrosine was dissolved in MilliQ water to obtain a tyrosine solution.
  • the tyrosine solution was dispensed and stored frozen.
  • Solution B 500 mL was prepared and used as solution B.
  • Solution A and solution B were mixed at a ratio of 1: 1 to prepare PH 6.8 1/15 M phosphate buffer.
  • Cold water extract A and cold water extract B were each diluted with MilliQ water to prepare sample solutions of various concentrations.
  • Four 10mL screw cap test tubes were prepared for each concentration of sample solution. Of the four test tubes, two were for sample (+) and the remaining two were for sample (one).
  • four control screw test tubes were prepared, two of which were used for control (+) and the other two were used for control (one).
  • (+) means calorie with tyrosine solution
  • (-) means no addition of tyrosine solution.
  • Prepare reaction solutions for each test tube. Table 1 shows the composition of the reaction solution in each test tube.
  • tyrosinase About the required amount of tyrosinase was placed in a falcon tube and weighed. MilliQ water was added according to the amount of tyrosinase to prepare a 1000 unit / mL enzyme solution. The enzyme solution was prepared immediately before use. For all test tubes, 0.5 mL of the enzyme solution was added, the test tube lid was closed, and vortexing was performed every 15 seconds.
  • test tubes were set in a constant temperature shaker maintained at 37 ° C and shaken at 70 / min for 1 hour. Constant-temperature shaker force All test tubes were removed, mixed a few times, and then ice-cooled for 5 minutes to stop the enzyme reaction. To a well-cooled 96-well plate, 300 L of each tube solution was added with care not to warm it, and the absorbance at 475 nm was measured using a plate reader. Zero adjustment was performed with MilliQ water.
  • FIG. 3 is a graph showing the tyrosinase activity inhibition rate (%) of cold water extract A and cold water extract B.
  • Kodiic acid MilliQ water dilution was used as a positive control.
  • the tyrosinase activity inhibition rate increased in the sample solution of cold water extract A and cold water extract B. That is, it was revealed that the cold water extract A and the cold water extract B have an inhibitory effect on tyrosinase activity.
  • the sample to which 400 ppm of cold water extract A was added showed a remarkable inhibitory effect on tyrosinase activity compared to the control.
  • cold water extract C obtained in Production Example 1 was used as a sample.
  • the test was performed in substantially the same procedure as in Example 11.
  • FIG. 4 is a graph showing the tyrosinase activity inhibition rate (%) of cold water extract C as a relative value when the tyrosinase activity inhibition rate of the control (MilliQ water) is 0%.
  • the tyrosinase activity inhibition rate decreased in a concentration-dependent manner in the cold water extract C sample solution. In other words, it was revealed that cold water extract C has a concentration-dependent tyrosinase activity inhibitory action.
  • the plate was placed in an incubator and cultured at 37 ° C for 24 hours.
  • a sample dissolved in DMSO was added to the plate and cultured under the same conditions for 3 days.
  • the case where DMS O was added instead of the sample was used as a control, and the case where arbutin was added was used as a positive control.
  • a normal human skin three-dimensional model (MEL-300A (Asian donor), Lot, No. 6761, Kurabo Industries) was irradiated with UVB at 31.5 mj / cm 2 .
  • UV irradiation was performed with a transilluminator DT-20MP (ATTO).
  • the UV amount was measured by attaching a UVX-31 detector to a UVX digital radiometer (UV P Inc.) and measuring the intensity at UV 310 nm.
  • FIG. 11 is a perspective view (a) and a sectional view (b) showing the structure of the skin model cup.
  • Skin The model cup 100 comprises a culture insert 4 inside a tissue culture well 2.
  • a membrane 8 is stretched horizontally inside the culture insert, and the tissue culture well 2 is filled with the culture medium 6 up to the height of the membrane 8.
  • a tissue 10 composed of human normal epidermal keratinocytes and melanocytes is placed on the membrane 8 in the culture insert 4. To skin model cup 100 In this case, the tissue 10 is nourished through the membrane 8 through the membrane 8.
  • the sample solution was added to the culture solution of the skin model.
  • the case where a culture solution was added instead of the sample solution was used as a control.
  • a skin model cup was placed in one, and culture was started at 37 ° C.
  • the culture was performed using EPI-100-LL MM long-term maintenance medium. After culturing for 24 hours, the medium was changed, and the sample solution was added again. Three days later, the medium was changed again, and the sample solution was added. Two more days later, the medium was changed and the sample was added, and the cytotoxicity test was conducted 24 hours later.
  • the cytotoxicity test was conducted by MTT Atsey.
  • the MTT Atsey was conducted according to the following procedure.
  • the skin model cup was washed 3 times with PBS250. Place tissue in a 24-well plate containing 300 MTT solution and incubate at 37 ° C in an incubator adjusted to 5% CO.
  • FIG. 12 is a graph showing the survival rate of tissue cells when cold water extract A is added as a relative value when the survival rate of the control is 100%.
  • Fig. 13 is a photograph showing the melanin production status of the control
  • Fig. 14 is a photo showing the melanin production status when a 0.08 wt% solution of cold water extract A is added
  • Fig. 15 is a cold water extract. It is a photograph which shows the melanin production
  • a whitening agent containing a hop extract and particularly excellent in whitening effect is provided.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Birds (AREA)
  • Molecular Biology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Dermatology (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un agent de blanchiment de la peau comprenant un extrait aqueux froid d'un tissu de houblon en tant qu'ingrédient actif. De préférence, l'extrait aqueux froid contient au moins un glucoside flavonoïde choisi dans le groupe comprenant l'astragaline, l'astragaline malonylglucoside, l'isoquercitrine, l'isoquercitrine malonylglucoside, la quercétine malonylglucoside, le kaempférol rutinoside, le kaempférol malonylglucoside, la rutine et le glycoside de phloroacylphénone.
PCT/JP2007/066382 2006-09-01 2007-08-23 Agent de blanchiment de la peau WO2008026507A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2008532036A JPWO2008026507A1 (ja) 2006-09-01 2007-08-23 美白剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006-238049 2006-09-01
JP2006238049 2006-09-01

Publications (1)

Publication Number Publication Date
WO2008026507A1 true WO2008026507A1 (fr) 2008-03-06

Family

ID=39135790

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/066382 WO2008026507A1 (fr) 2006-09-01 2007-08-23 Agent de blanchiment de la peau

Country Status (3)

Country Link
JP (1) JPWO2008026507A1 (fr)
TW (1) TW200824718A (fr)
WO (1) WO2008026507A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008208073A (ja) * 2007-02-27 2008-09-11 Gifu Prefecture Kenkyu Kaihatsu Zaidan メラニン産生抑制剤及び皮膚外用剤
JP2009298765A (ja) * 2008-03-14 2009-12-24 Oriza Yuka Kk 美肌用遺伝子発現促進剤並びにそれを用いた保湿用組成物及び美肌用組成物
JP2012153659A (ja) * 2011-01-27 2012-08-16 Akita Univ ホップ葉抽出物およびその製造方法
JP2013150575A (ja) * 2012-01-25 2013-08-08 Maruha Nichiro Seafoods Inc 魚類の肉色改善飼料および肉色改善方法
JP2014204711A (ja) * 2013-03-19 2014-10-30 国立大学法人 千葉大学 三次元培養皮膚モデルの製造方法およびその利用
WO2018230910A1 (fr) * 2017-06-12 2018-12-20 (주)아모레퍼시픽 Composition de blanchiment comprenant un nouveau composé à base de kaempférol dérivé de thé post-fermenté
WO2019098352A1 (fr) * 2017-11-17 2019-05-23 ロート製薬株式会社 Composition cosmétique, méthode de criblage, et méthode cosmétique
US11197878B2 (en) 2017-06-12 2021-12-14 Amorepacific Corporation Anti-inflammatory composition including novel quercetin-based compound
US11248017B2 (en) 2017-06-12 2022-02-15 Amorepacific Corporation Anti-inflammatory composition including novel kaempferol-based compound derived from post-fermented tea
US11306117B2 (en) 2017-06-12 2022-04-19 Amorepacific Corporation Whitening composition containing novel quercetin-based compound

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03193712A (ja) * 1989-12-22 1991-08-23 Kobayashi Kose Co Ltd 化粧料
JPH0899859A (ja) * 1994-09-30 1996-04-16 Kose Corp 皮膚外用剤
WO2006093194A1 (fr) * 2005-03-03 2006-09-08 Sapporo Breweries Limited Composition antiallergique
WO2006093202A1 (fr) * 2005-03-03 2006-09-08 Sapporo Breweries Limited Glycoside de phloroacylphénone, procédé de synthèse de ladite substance, agent antiallergisant et antioxydant

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03193712A (ja) * 1989-12-22 1991-08-23 Kobayashi Kose Co Ltd 化粧料
JPH0899859A (ja) * 1994-09-30 1996-04-16 Kose Corp 皮膚外用剤
WO2006093194A1 (fr) * 2005-03-03 2006-09-08 Sapporo Breweries Limited Composition antiallergique
WO2006093202A1 (fr) * 2005-03-03 2006-09-08 Sapporo Breweries Limited Glycoside de phloroacylphénone, procédé de synthèse de ladite substance, agent antiallergisant et antioxydant

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BHANDARI P.R.: "IDENTIFICATION OF FLAVONOIDS IN HOPS (HUMULUS LUPULUS LINNE) BY THIN-LAYER CHROMATOGRAPHY", JOURNAL OF CHROMATOGRAPHY, vol. 16, no. 1, 1964, pages 130 - 135, XP003021344 *
HOQUE E. ET AL.: "Natural UV-screening mechanisms of Norway spruce (Picea abies (L.) Karts.) needles", PHOTOCHEMISTRY AND PHOTOBIOLOGY, vol. 69, no. 2, 1999, pages 177 - 192, XP003021342 *
LAI J.S. ET AL.: "Studies on the constituents of whiten and sunscreen of some Chinese herbs", SCIENTIFIC CONFERENCE OF THE ASIAN SOCIETIES OF COSMETIC SCIENTISTS, vol. 3RD, 23 May 1997 (1997-05-23) - 24 May 1997 (1997-05-24), pages 25 - 27, XP003021343 *
MCMURROUGH I. ET AL.: "Quantitative analysis of hop flavonols using high-performance liquid chromatography", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 30, no. 6, 1982, pages 1102 - 1106, XP001181943 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008208073A (ja) * 2007-02-27 2008-09-11 Gifu Prefecture Kenkyu Kaihatsu Zaidan メラニン産生抑制剤及び皮膚外用剤
JP2009298765A (ja) * 2008-03-14 2009-12-24 Oriza Yuka Kk 美肌用遺伝子発現促進剤並びにそれを用いた保湿用組成物及び美肌用組成物
JP2012153659A (ja) * 2011-01-27 2012-08-16 Akita Univ ホップ葉抽出物およびその製造方法
JP2013150575A (ja) * 2012-01-25 2013-08-08 Maruha Nichiro Seafoods Inc 魚類の肉色改善飼料および肉色改善方法
JP2014204711A (ja) * 2013-03-19 2014-10-30 国立大学法人 千葉大学 三次元培養皮膚モデルの製造方法およびその利用
JP2020523301A (ja) * 2017-06-12 2020-08-06 アモーレパシフィック コーポレーションＡｍｏｒｅｐａｃｉｆｉｃ Ｃｏｒｐｏｒａｔｉｏｎ 後発酵茶由来の新規なケンペロール系化合物を含む美白用組成物
CN110740722A (zh) * 2017-06-12 2020-01-31 株式会社爱茉莉太平洋 包含后发酵茶来源的新山柰酚类化合物的美白组合物
WO2018230910A1 (fr) * 2017-06-12 2018-12-20 (주)아모레퍼시픽 Composition de blanchiment comprenant un nouveau composé à base de kaempférol dérivé de thé post-fermenté
US10881599B2 (en) 2017-06-12 2021-01-05 Amorepacific Corporation Whitening composition including novel kaempferol-based compound derived from post-fermented tea
US11197878B2 (en) 2017-06-12 2021-12-14 Amorepacific Corporation Anti-inflammatory composition including novel quercetin-based compound
US11248017B2 (en) 2017-06-12 2022-02-15 Amorepacific Corporation Anti-inflammatory composition including novel kaempferol-based compound derived from post-fermented tea
US11306117B2 (en) 2017-06-12 2022-04-19 Amorepacific Corporation Whitening composition containing novel quercetin-based compound
JP7121758B2 (ja) 2017-06-12 2022-08-18 アモーレパシフィック コーポレーション 後発酵茶由来の新規なケンペロール系化合物を含む美白用組成物
CN110740722B (zh) * 2017-06-12 2023-02-21 株式会社爱茉莉太平洋 包含后发酵茶来源的山柰酚类化合物的美白组合物
WO2019098352A1 (fr) * 2017-11-17 2019-05-23 ロート製薬株式会社 Composition cosmétique, méthode de criblage, et méthode cosmétique
JPWO2019098352A1 (ja) * 2017-11-17 2021-01-14 ロート製薬株式会社 美容組成物、スクリーニング方法及び美容方法

Also Published As

Publication number Publication date
JPWO2008026507A1 (ja) 2010-01-21
TW200824718A (en) 2008-06-16

Similar Documents

Publication Publication Date Title
WO2008026507A1 (fr) Agent de blanchiment de la peau
EP2033528B1 (fr) Extrait d'airelle, procédé de préparation et utilisation correspondante
CA2396734C (fr) Extraction de flavonoides
JP4709205B2 (ja) 抗アレルギー組成物
US9745279B2 (en) Sirtuin activator
JP6666837B2 (ja) メトキシフラボンを含むＮＯＸ阻害剤及びＮＦκＢ阻害剤
US7507423B2 (en) Extraction of flavonoids
Hu et al. Efficacy evaluation of a Chinese bitter tea (Ilex latifolia Thunb.) via analyses of its main components
JP5627585B2 (ja) カナクギノキ由来抽出物、分画物または、化合物を含有する皮膚美白用組成物
JP2009173583A (ja) ＩｇＥ抗体産生抑制剤
JP2009013106A (ja) 炎症性サイトカイン産生抑制作用を有するキサントン誘導体、それらの製造方法、それからなる食品製剤、化粧品、抗炎症剤
KR101453609B1 (ko) 조팝나무잎으로부터 분리된 신규 헤미테르펜 글루코사이드 화합물 및 이의 항산화 및 항염 용도
WO2006093202A1 (fr) Glycoside de phloroacylphénone, procédé de synthèse de ladite substance, agent antiallergisant et antioxydant
JP2008208284A (ja) セラミド類含有組成物およびその製造方法
JP6436337B2 (ja) エラスチン産生作用を呈するケルセチン誘導体及びその製造方法
JP5190926B2 (ja) ツバキ由来のアントシアニン色素、その製造方法及び用途、並びにツバキの品種識別方法
JP2011074062A (ja) 抗ｉ型アレルギー剤
KR102547632B1 (ko) 고농도 페난트렌 유도체를 함유하는 마 껍질 추출물, 이의 제조 방법 및 이를 포함하는 식품 조성물
JP7442079B2 (ja) テロメラーゼ発現増強剤
AU769739B2 (en) Extraction of flavonoids
KR20240077770A (ko) 아카세틴, 아피제닌 및 루테올린의 함량이 증가된 감국 추출물의 제조방법과 생물전환된 감국 추출물 및 분획물
TW202200185A (zh) 用以抑制皮膚屏障功能的降低或改善該功能之組成物、用以抑制第４型膠原蛋白之表現的降低或改善該表現之組成物，及具有抑制皮膚屏障功能的降低或改善該功能之作用的物質之篩選方法
KR101042005B1 (ko) 비목나무 유래 화합물, 이의 분리 방법 및 이를 함유하는 피부 미백용 조성물
Abbasi et al. Phytochemical contents of wild edible vegetables
CN111432798A (zh) 包含木槿花提取物的用于护理由微尘引起的皮肤细胞损伤或用于抑制抗菌肽的组合物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07806011

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008532036

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07806011

Country of ref document: EP

Kind code of ref document: A1